Janux Therapeutics, Inc. (NASDAQ: JANX) is listed among the Best Get Rich Fast Stocks to Buy Right Now. Analysts have given JANX a consensus buy rating, with price targets indicating up to 948% upside potential. Barclays recently revised their price target to $29, implying a 103% upside. JANX008, an EGFR-targeted TRACTr, is undergoing a Phase 1 study for multiple solid tumors. The completion of the Phase 1a dose-escalation portion has led to the initiation of expansion cohorts for further evaluation. JANX is a California-based biopharmaceutical company focused on developing immunotherapies for cancer patients. While JANX shows investment potential, other AI stocks may offer greater upside.

Read more at Yahoo Finance: Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)